Navigation Links
Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
Date:8/14/2008

he treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, respectively, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical stu
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Clinical Trials Bootcamp Announces Inaugural Meeting
2. Aon eSolutions Launches Clinical Trials Module
3. Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders
4. NewCardio Announces Positive Results From Third Clinical Validation Study
5. Isis Initiates Clinical Trial of CRP Drug
6. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
7. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
8. Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent
9. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
10. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
11. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes ... investigational drug for cancer, is designed for injection into ... Its oncology focus is on melanoma, breast cancer and ... trials of PV-10 as a therapy for metastatic melanoma, ... dermatitis and psoriasis. This summer, the ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 /PRNewswire/ ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting ... Under the terms of the collaboration, Foundation ... laboratory component of Foundation Medicine,s FoundationOne® assay at the ...
(Date:10/20/2014)... 2014  Luoxis Diagnostics, Inc., a subsidiary of ... that its academic collaborators will present several peer-reviewed ... its novel RedoxSYS Diagnostic System, a first-in-class platform ... in response to injury or illness.  A poster ... clinical marker will be presented by Christopher ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... the risk of cardiovascular hospitalization or death by 24 ... Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and ... that the ATHENA trial was published in the New ... (dronedarone), in addition to standard therapy, significantly reduced the ...
... a study published in The American Journal of ... Clinic psychiatrist Mark Frye, M.D., attempted to identify what ... to experience treatment-emergent mania (TEM).Bipolar disorder, also known as ... mood instability that can be serious and disabling. The ...
Cached Medicine Technology:New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 2New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 3New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 4New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 5New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 6Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder 2Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder 3
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... who was diagnosed with Ebola while working for NBC News ... can leave the special isolation unit at Nebraska Medical Center in ... the hospital said Tuesday. A blood test confirmed by the ... 33, can head home to Providence, R.I., NBC News ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute ... to repair a damaged mitral valve as the heart ... developed by Abbott Vascular , is designed to ... condition in which the heart’s mitral valve leaflets fail ... the heart’s left ventricle into the left atrium. The ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... through an animal study that Aspartame can cause lymphoma, ... five 20-ounce bottles of diet soda sweetened with aspartame ... ,The study would be published in March issue ... journal., ,The method and sample adopted were feeding ...
... short breaks can go a long way in making ... study conducted by Massachusetts Institute researchers. // ... Massachusetts Institute of Technology in Cambridge, found that rats' ... pause briefly to rest., ,They suggest that eliminating ...
... cell research in the state with the approval of 61% ... have impeded the initiative. // ,The officials now ... will be initiated. Zach Hall, president of the California Institute ... would commence the project as soon as possible. ...
... Howard has allocated $1.1 billion in health reforms. But his ... ,Mr. Howard said that there was more mental illness previously ... thing is to move on with one’s life. ... ill-informed. ,Though he said that in reality mental ...
... Honolulu: The Hawaii State Hospital has gone down the ranks ... crowding, a status report has revealed//. The status report quotes, ... to meet the June 30th deadline, required to bring the ... had received a one-year extended timeframe till June 30 to ...
... the help of prisoners from Beur jail in Patna to ... near the jail and begged for money to fulfill the ... was kidnapped in Phulwarisharief while he was on his way ... to use their contacts outside the jail to help trace ...
Cached Medicine News:Health News:Task Learning Made Simple By Taking Short Breaks 2Health News:Momentum of Stem cell research impeded by legal challenges 2
Multispot HIV-1/HIV-2 is a rapid indirect EIA using recombinant and peptide antigens for simultaneous detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies in human serum or plasma....
Bio-Rad's Genetic Systems™ HBsAg EIA 3.0 screening and confirmatory assays offer outstanding sensitivity and early detection of HBV infection, helping to meet your testing criteria....
The most compact revolutionary innovation in hematology. 3 Part DIFF + CRP measurement on whole blood....
... Evolis™ is a self contained microplate ... based EIA assays. The system is dedicated ... encountered in todays busy laboratory. The system ... of EIA assays that satisfy their microplate ...
Medicine Products: